- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05490459
Jewel Electrophysiology (EP) Lab Study
February 15, 2023 updated by: Element Science, Inc.
Single arm open label evaluation of the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD) defibrillation waveform in adult cardiac patients.
Study Overview
Status
Enrolling by invitation
Conditions
Intervention / Treatment
Detailed Description
The objective of this study is to demonstrate the safety and clinical effectiveness of the Jewel EP Lab System in terminating life-threatening VT or VF with a single transthoracic defibrillation shock.
Study Type
Interventional
Enrollment (Anticipated)
18
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Prague, Czechia
- Nemocnice Na Homolce Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects of both genders of at least 18 years of age.
- Subjects who are scheduled for a standard EP clinical procedure where fast VT or VF may spontaneously occur or may be induced.
Exclusion Criteria:
- Subjects who may require sterile access to the right upper pectoral or lower left torso regions during the planned EP procedure.
- Subjects who have taken amiodarone in the past 3 months.
- Subjects with an existing unipolar pacemaker.
- Subjects who exhibit a left ventricular ejection fraction (LVEF) less than 20% (as assessed by techniques such as echocardiography, magnetic resonance imaging, or radionuclide angiography) within the last 6 months.
- Subjects who have been diagnosed with heart failure (Class IV) or experienced an acute heart failure exacerbation within the previous 30 days.
- Subjects who exhibit unstable angina.
- Subjects with atrial fibrillation with contraindication to anticoagulation or improper anticoagulation management.
- Subjects who are participating in an investigational study of a drug, biologic, or device not currently approved for marketing.
- Subjects who are allergic to or have had a known adverse reaction to medical adhesives.
- Subjects who have active skin breakdown, erythema, or other signs of infection in the pectoral or torso regions where the study device is applied.
- Subjects with a lower abdomen circumference of less than 68.5 cm or greater than 142 cm.
- Females who are pregnant or breastfeeding, or planning to be pregnant in the next 12 months.
- Subjects who cannot provide or have diminished capacity to provide informed consent.
- Any condition that an Investigator believes would interfere with the intent of the study or is not in the best interest of the patient.
- Any patient that according to the Declaration of Helsinki is unsuitable for enrollment.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment
Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
|
Automatic external cardioverter defibrillator that monitors patients at risk for SCA and provides a therapeutic shock if needed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Effectiveness of the Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
Time Frame: Immediately following defibrillation with the study device
|
Percent of successful terminations of life-threatening VT or VF
|
Immediately following defibrillation with the study device
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 28, 2022
Primary Completion (Actual)
December 31, 2022
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
July 27, 2022
First Submitted That Met QC Criteria
August 4, 2022
First Posted (Actual)
August 5, 2022
Study Record Updates
Last Update Posted (Estimate)
February 16, 2023
Last Update Submitted That Met QC Criteria
February 15, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR-2038
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sudden Cardiac Arrest
-
Boston Scientific CorporationCompletedPrimary Prevention of Sudden Cardiac Arrest | Secondary Prevention of Sudden Cardiac ArrestUnited States
-
Boston Scientific CorporationCompletedPrimary Prevention of Sudden Cardiac Arrest | Secondary Prevention of Sudden Cardiac ArrestUnited States, Canada, Australia
-
Unity Health TorontoSunnybrook Health Sciences Centre; University of British Columbia; Alberta Health... and other collaboratorsCompleted
-
Karolinska InstitutetCompletedOut-Of-Hospital Cardiac Arrest | Cardiac Arrest, SuddenSweden
-
Sistema d'Emergències MèdiquesHospital Vall d'HebronUnknown
-
Udayana UniversityCompletedCardiac Arrest, Sudden | In-hospital Cardiac Arrest | Cardiopulmonary Arrest | Cardiopulmonary FailureIndonesia
-
Rambam Health Care CampusUnknown
-
Zoll Medical CorporationCompletedHeart Failure | Sudden Cardiac Death | Sudden Cardiac Arrest | Heart Failure Low OutputFrance, United States, Germany, Austria
-
Duke UniversityUniversity of Washington; University of Toronto; Virginia Commonwealth UniversityNot yet recruitingCardiac Arrest | Sudden Cardiac Arrest
Clinical Trials on Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)
-
Zoll Medical CorporationCompletedHeart Failure; With DecompensationUnited States, Austria, Germany, Poland
-
University of California, San FranciscoZoll Medical CorporationCompletedMyocardial Infarction | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Dysfunction | Sudden DeathUnited States, Germany, Poland
-
Zoll Medical CorporationUniversity of RochesterCompletedIschemic Heart FailureUnited States
-
Zoll Medical CorporationTerminatedSudden Cardiac Death | Sudden Cardiac ArrestUnited States
-
Kestra Medical Technologies, Inc.Regulatory and Clinical Research Institute IncCompletedCardiac Arrest, SuddenUnited States
-
Zoll Medical CorporationTerminatedMyocardial Ischemia | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Dysfunction | Sudden Cardiac DeathUnited States
-
Zoll Medical CorporationCompletedHeart Failure | Ventricular Fibrillation | Ventricular Tachycardia | Ventricular Dysfunction | Sudden Death | Sudden Cardiac ArrestIsrael, United States
-
Zoll Medical CorporationCompletedHeart Failure | Sudden Cardiac Death | Sudden Cardiac Arrest | Heart Failure Low OutputFrance, United States, Germany, Austria
-
Zoll Medical CorporationRecruitingHeart FailureUnited States